Schonfeld Strategic Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3M	Sell	185,629 -6,377	-3%	-$498K	0.1%	225
2025 Q4	$15.2M	Buy	192,006 +170,206	+781%	+$14.7M	0.07%	256
2025 Q3	$2M	Sell	21,800 -15,748	-42%	-$1.28M	0.01%	1032
2025 Q2	$2.45M	Sell	37,548 -37,444	-50%	-$2.44M	0.02%	872
2025 Q1	$5.02M	Buy	+74,992	New	+$4.48M	0.03%	521
2024 Q1	–	Sell	-3,831	Closed	-$211K	–	2045
2023 Q4	$211K	Sell	3,831 -27,969	-88%	-$1.54M	﹤0.01%	1522
2023 Q3	$1.85M	Sell	31,800 -18,200	-36%	-$1.05M	0.01%	853
2023 Q2	$2.69M	Buy	50,000 +20,250	+68%	+$898K	0.02%	662
2023 Q1	$1.18M	Sell	29,750 -10,096	-25%	-$426K	0.01%	885
2022 Q4	$1.6M	Buy	+39,846	New	+$1.5M	0.01%	917

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schonfeld Strategic Advisors's ANIP Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its ANI Pharmaceuticals (ANIP) stake by 3.3% in Q1 2026, selling an estimated $498K and leaving 185,629 shares worth $14.3M. The position accounts for 0.1% of the portfolio, ranked #225.

Schonfeld Strategic Advisors first reported a position in ANIP in Q4 2022 and has held it in 10 quarters since. The position peaked at $15.2M in Q4 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Schonfeld Strategic Advisors held 185,629 shares of ANI Pharmaceuticals worth $14.3M as of Q1 2026.
Schonfeld Strategic Advisors sold 6,377 ANI Pharmaceuticals shares in Q1 2026, an estimated $498K.
ANI Pharmaceuticals made up 0.1% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #225 holding.
Schonfeld Strategic Advisors first reported a position in ANI Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
Schonfeld Strategic Advisors's ANI Pharmaceuticals position peaked at $15.2M in Q4 2025.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.